Reverse genetics approaches to combat pathogenic arenaviruses

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 239-250

  de la Torre, Juan C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antivirals; Arenaviruses; Junin virus; Lassa virus; Lymphocytic choriomeningitis virus; Reverse genetics

Indexed keywords

ANTIVIRUS AGENT; CIS ACTING ELEMENT; DNA DIRECTED DNA POLYMERASE ALPHA; MESSENGER RNA; MYRISTIC ACID DERIVATIVE; PHENOTHIAZINE DERIVATIVE; RECOMBINANT VACCINE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; TARIBAVIRIN; TRANS ACTING FACTOR; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANEMIA; ARENAVIRUS; CYTOLOGY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HIGH THROUGHPUT SCREENING; HUMAN; JUNIN VIRUS; LASSA VIRUS; LIFE CYCLE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; RNA REPLICATION; RNA SYNTHESIS; VESICULAR STOMATITIS VIRUS; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; DRUG EVALUATION, PRECLINICAL; HUMANS; PROMOTER REGIONS, GENETIC; VIRAL VACCINES; VIRUS PHYSIOLOGICAL PHENOMENA;

ARENAVIRUS; JUNIN VIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 56649086666     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.08.002     Document Type: Review

References (144)

1. Andrei G., and De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 14 (1990) 287-299
2. Andrei G., and De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22 (1993) 45-75
3. Aza-Blanc P., Cooper C.L., Wagner K., Batalov S., Deveraux Q.L., and Cooke M.P. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell. 12 (2003) 627-637
4. Barton L.L., and Mets M.B. Lymphocytic choriomeningitis virus: pediatric pathogen and fetal teratogen. Pediatr. Infect. Dis. J. 18 (1999) 540-541
5. Barton L.L., and Mets M.B. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin. Infect. Dis. 33 (2001) 370-374
6. Barton L.L., Mets M.B., and Beauchamp C.L. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 187 (2002) 1715-1716
7. Basak S., Stewart N.A., Chretien M., and Basak A. Aminoethyl benzenesulfonyl fluoride and its hexapeptide (Ac-VFRSLK) conjugate are both in vitro inhibitors of subtilisin kexin isozyme-1. FEBS Lett. 573 (2004) 186-194
8. Bergthaler A., Gerber N.U., Merkler D., Horvath E., de la Torre J.C., and Pinschewer D.D. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog. 2 (2006) e51
9. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., and Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
10. Beyer W.R., Popplau D., Garten W., von Laer D., and Lenz O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 77 (2003) 2866-2872
11. Bodvard K., Mohlin J., and Knecht W. Recombinant expression, purification, and kinetic and inhibitor characterisation of human site-1-protease. Protein Exp. Purif. 51 (2007) 308-319 (Epub 2006 August 2001)
12. Boger D.L. Solution-phase synthesis of combinatorial libraries designed to modulate protein-protein or protein-DNA interactions. Bioorg. Med. Chem. 11 (2003) 1607-1613
13. Boger D.L., Desharnais J., and Capps K. Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. Angew. Chem. Int. Ed. Engl. 42 (2003) 4138-4176
14. Boger D.L., Ducray P., Chai W., Jiang W., and Goldberg J. Higher order iminodiacetic acid libraries for probing protein-protein interactions. Bioorg. Med. Chem. Lett. 8 (1998) 2339-2344
15. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Amanda Lund S., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., and Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. (2005)
16. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen Jr. E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., and Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287 (2002) 2391-2405
17. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
18. Buchmeier M.J., Peters C.J., and de la Torre J.C. Arenaviridae: the viruses and their replication. In: Knipe D.M., and Holey P.M. (Eds). Fields Virology. fifth ed. vol. 2 (2007) 1792-1827
19. Cameron C.E., and Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr. Opin. Infect. Dis. 14 (2001) 757-764
20. Candurra N.A., Maskin L., and Damonte E.B. Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res. 31 (1996) 149-158
21. Capul A.A., Perez M., Burke E., Kunz S., Buchmeier M.J., and de la Torre J.C. Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J. Virol. 81 (2007) 9451-9460
22. Conzelmann K.K. Reverse genetics of mononegavirales. In: Kawaoka Y. (Ed). Curr. Top. Microbiol. Immunol. 283 (2004) 1-41
23. Cordo S.M., Candurra N.A., and Damonte E.B. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1 (1999) 609-614
24. Cornu T.I., and de la Torre J.C. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J. Virol. 75 (2001) 9415-9426
25. Cornu T.I., and de la Torre J.C. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J. Virol. 76 (2002) 6678-6688
26. Cornu T.I., Feldmann H., and de la Torre J.C. Cells expressing the RING finger Z protein are resistant to arenavirus infection. J. Virol. 78 (2004) 2979-2983
27. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y.N., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
28. Damonte E.B., and Coto C.E. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv. Virus Res. 58 (2002) 125-155
29. Dimcheff D.E., Askovic S., Baker A.H., Johnson-Fowler C., and Portis J.L. Endoplasmic reticulum stress is a determinant of retrovirus-induced spongiform neurodegeneration. J. Virol. 77 (2003) 12617-12629
30. Dimcheff D.E., Faasse M.A., McAtee F.J., and Portis J.L. Endoplasmic reticulum (ER) stress induced by a neurovirulent mouse retrovirus is associated with prolonged BiP binding and retention of a viral protein in the ER. J. Biol. Chem. 279 (2004) 33782-33790 (Epub 32004 June 33783)
31. Djavani M., Yin C., Lukashevich I.S., Rodas J., Rai S.K., and Salvato M.S. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J. Hum. Virol. 4 (2001) 103-108
32. Eichler R., Lenz O., Strecker T., Eickmann M., Klenk H.D., and Garten W. Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep. 4 (2003) 1084-1088
33. Eichler R., Lenz O., Strecker T., Eickmann M., Klenk H.D., and Garten W. Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region. J. Biol. Chem. 279 (2004) 12293-12299
34. Elagoz A., Benjannet S., Mammarbassi A., Wickham L., and Seidah N.G. Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J. Biol. Chem. 277 (2002) 11265-11275 (Epub 12001 December 11226)
35. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
36. Enria D.A., and Barrera Oro J.G. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263 (2002) 239-261
37. Enria D.A., Briggiler A.M., and Sanchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78 (2008) 132-139
38. Fischer S.A., Graham M.B., Kuehnert M.J., Kotton C.N., Srinivasan A., Marty F.M., Comer J.A., Guarner J., Paddock C.D., DeMeo D.L., Shieh W.J., Erickson B.R., Bandy U., DeMaria Jr. A., Davis J.P., Delmonico F.L., Pavlin B., Likos A., Vincent M.J., Sealy T.K., Goldsmith C.S., Jernigan D.B., Rollin P.E., Packard M.M., Patel M., Rowland C., Helfand R.F., Nichol S.T., Fishman J.A., Ksiazek T., and Zaki S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354 (2006) 2235-2249
39. Fisher-Hoch S.P., Hutwagner L., Brown B., and McCormick J.B. Effective vaccine for Lassa fever. J. Virol. 74 (2000) 6777-6783
40. Flatz L., Bergthaler A., de la Torre J.C., and Pinschewer D.D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4663-4668
41. Freed E.O. Viral late domains. J. Virol. 76 (2002) 4679-4687
42. Freedman D.O., and Woodall J. Emerging infectious diseases and risk to the traveler. Med. Clin. North Am. 83 (1999) 865-883
43. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 (2004) S110-121
44. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Stroher U., Fernando L., Daddario K.M., Guttieri M.C., Mothe B.R., Larsen T., Hensley L.E., Jahrling P.B., and Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2 (2005) e183
45. Ghosh R.N., DeBiasio R., Hudson C.C., Ramer E.R., Cowan C.L., and Oakley R.H. Quantitative cell-based high-content screening for vasopressin receptor agonists using transfluor technology. J. Biomol. Screen. 10 (2005) 476-484
46. Goldstein J.L., Rawson R.B., and Brown M.S. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch. Biochem. Biophys. 397 (2002) 139-148
47. Hass M., Golnitz U., Muller S., Becker-Ziaja B., and Gunther S. Replicon system for Lassa virus. J. Virol. 78 (2004) 13793-13803
48. Hass M., Westerkofsky M., Muller S., Becker-Ziaja B., Busch C., and Gunther S. Mutational analysis of the Lassa virus promoter. J. Virol. 80 (2006) 12414-12419
49. Hermann T. Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew. Chem. Int. Ed. Engl. 39 (2000) 1890-1904
50. Hermann T., and Westhof E. Rational drug design and high-throughput techniques for RNA targets. Comb. Chem. High Throughput Screen 3 (2000) 219-234
51. Holmes G.P., McCormick J.B., Trock S.C., Chase R.A., Lewis S.M., Mason C.A., Hall P.A., Brammer L.S., Perez-Oronoz G.I., McDonnell M.K., et al. Lassa fever in the United States. Investigation of a case and new guidelines for management. N. Engl. J. Med. 323 (1990) 1120-1123
52. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 33 (2001) 1707-1712
53. Isler J.A., Skalet A.H., and Alwine J.C. Human cytomegalovirus infection activates and regulates the unfolded protein response. J. Virol. 79 (2005) 6890-6899
54. Jahrling P.B., and Peters C.J. Lymphocytic choriomeningitis virus. A neglected pathogen of man. Arch. Pathol. Lab. Med. 116 (1992) 486-488
55. Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., Fair J., Guttieri M.C., Ferro P., Imes T., Monagin C., Garry R.F., and Bausch D.G. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78 (2008) 103-115
56. Kiley M.P., Lange J.V., and Johnson K.M. Protection of rhesus monkeys from Lassa virus by immunisation with closely related arenavirus. Lancet 2 (1979) 738
57. Kilgore P.E., Ksiazek T.G., Rollin P.E., Mills J.N., Villagra M.R., Montenegro M.J., Costales M.A., Paredes L.C., and Peters C.J. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 24 (1997) 718-722
58. Kunz S., Borrow P., and Oldstone M.B. Receptor structure, binding, and cell entry of arenaviruses. Curr. Top. Microbiol. Immunol. 262 (2002) 111-137
59. Kunz S., Edelmann K.H., de la Torre J.-C., Gorney R., and Oldstone M.B.A. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314 (2003) 168-178
60. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., and Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arena viruses. J. Biol. Chem. (2008)
61. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B., and de La Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 74 (2000) 3470-3477
62. Lee K.J., Perez M., Pinschewer D.D., and de la Torre J.C. Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J. Virol. 76 (2002) 6393-6397
63. Lenz O., ter Meulen J., Klenk H.D., Seidah N.G., and Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 12701-12705
64. Leyssen P., De Clercq E., and Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78 (2008) 9-25
65. Lopez N., and Franze-Fernandez M.T. A single stem-loop structure in Tacaribe arenavirus intergenic region is essential for transcription termination but is not required for a correct initiation of transcription and replication. Virus Res. 124 (2007) 237-244
66. Lopez N., Jacamo R., and Franze-Fernandez M.T. Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: z protein is an inhibitor of these processes. J. Virol. 75 (2001) 12241-12251
67. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., Brasky K., Geiger R., Hubbard G.B., Bryant J., and Salvato M.S. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79 (2005) 13934-13942
68. Luytjes W., Krystal M., Enami M., Pavin J.D., and Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59 (1989) 1107-1113
69. AHF Study Group. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J. Infect. Dis. 177 (1998) 277-283
70. Matloubian M., Somasundaram T., Kolhekar S.R., Selvakumar R., and Ahmed R. Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J. Exp. Med. 172 (1990) 1043-1048
71. McCarthy S.E., Licata J.M., and Harty R.N. A luciferase-based budding assay for Ebola virus. J. Virol. Methods 137 (2006) 115-119
72. McCormick J.B., and Fisher-Hoch S.P. Lassa fever. In: Oldstone M.B. (Ed). Arenaviruses I vol. 262 (2002), Springer-Verlag, Berlin, Heidelberg, New York 75-110
73. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., and Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314 (1986) 20-26
74. McKee Jr. K.T., Huggins J.W., Trahan C.J., and Mahlandt B.G. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob. Agents Chemother. 32 (1988) 1304-1309
75. Medigeshi G.R., Lancaster A.M., Hirsch A.J., Briese T., Lipkin W.I., Defilippis V., Fruh K., Mason P.W., Nikolich-Zugich J., and Nelson J.A. West Nile virus infection activates the unfolded protein response leading to CHOP induction and apoptosis. J. Virol. 8 (2007) 8
76. Mets M.B., Barton L.L., Khan A.S., and Ksiazek T.G. Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am. J. Ophthalmol. 130 (2000) 209-215
77. Meyer B.J., de La Torre J.C., and Southern P.J. Arenaviruses: genomic RNAs, transcription, and replication. In: Oldstone M.B. (Ed). Arenaviruses I vol. 262 (2002), Springer-Verlag, Berlin, Heidelberg 139-149
78. Neuman B.W., Adair B.D., Burns J.W., Milligan R.A., Buchmeier M.J., and Yeager M. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. J. Virol. 79 (2005) 3822-3830
79. Neumann G., Whitt M.A., and Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA-what have we learned?. J. Gen. Virol. 83 (2002) 2635-2662
80. Oldstone M.B. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. In: Oldstone M.B. (Ed). Arenaviruses vol. 263 (2002) 83-118
81. Paddison P.J., Silva J.M., Conklin D.S., Schlabach M., Li M., Aruleba S., Balija V., O'Shaughnessy A., Gnoj L., Scobie K., Chang K., Westbrook T., Cleary M., Sachidanandam R., McCombie W.R., Elledge S.J., and Hannon G.J. A resource for large-scale RNA-interference-based screens in mammals. Nature 428 (2004) 427-431
82. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 107 (2005) 165-171
83. Pasquato A., Pullikotil P., Asselin M.C., Vacatello M., Paolillo L., Ghezzo F., Basso F., Di Bello C., Dettin M., and Seidah N.G. The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J. Biol. Chem. 281 (2006) 23471-23481 (Epub 22006 June 23421)
84. Pavio N., Romano P.R., Graczyk T.M., Feinstone S.M., and Taylor D.R. Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK. J. Virol. 77 (2003) 3578-3585
85. Perez M., Craven R.C., and de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12978-12983
86. Perez M., and de la Torre J.C. Characterization of the Genomic Promoter of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus (LCMV). J. Virol. 77 (2002) 1184-1194
87. Perez M., Greenwald D.L., and de la Torre J.C. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J. Virol. 78 (2004) 11443-11448
88. Peters C.J. Human infection with arenaviruses in the Americas. In: Oldstone M.B. (Ed). Arenaviruses I vol. 262 (2002), Springer-Verlag, Berlin, Heidelberg 65-74
89. Peters C.J. Lymphocytic choriomeningitis virus-an old enemy up to new tricks. N. Engl. J. Med. 354 (2006) 2208-2211
90. Pinschewer D.D., Perez M., and de la Torre J.C. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J. Virol. 77 (2003) 3882-3887
91. Pinschewer D.D., Perez M., and de la Torre J.C. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J. Virol. 79 (2005) 4519-4526
92. Pinschewer D.D., Perez M., Sanchez A.B., and de la Torre J.C. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 7895-7900
93. Poch O., Sauvaget I., Delarue M., and Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8 (1989) 3867-3874
94. Pornillos O., Garrus J.E., and Sundquist W.I. Mechanisms of enveloped RNA virus budding. Trends Cell Biol. 12 (2002) 569-579
95. Pullikotil P., Vincent M., Nichol S.T., and Seidah N.G. Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein. J. Biol. Chem. 279 (2004) 17338-17347 (Epub 12004 February 17316)
96. Pushko P., Geisbert J., Parker M., Jahrling P., and Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75 (2001) 11677-11685
97. Rawson R.B. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem. Soc. Symp. (2003) 221-231
98. Rawson R.B. The SREBP pathway-insights from insigs and insects. Nat. Rev. Mol. Cell. Biol. 4 (2003) 631-640
99. Repik P., Flamand A., and Bishop D.H. Synthesis of RNA by mutants of vesicular stomatitis virus (Indiana serotype) and the ability of wild-type VSV New Jersey to complement the VSV Indiana ts G I-114 transcription defect. J. Virol. 20 (1976) 157-169
100. Riviere Y., Ahmed R., Southern P., and Oldstone M.B. Perturbation of differentiated functions during viral infection in vivo. II. Viral reassortants map growth hormone defect to the S RNA of the lymphocytic choriomeningitis virus genome. Virology 142 (1985) 175-182
101. Riviere Y., Ahmed R., Southern P.J., Buchmeier M.J., and Oldstone M.B. Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J. Virol. 55 (1985) 704-709
102. Robertson D.L., and Joyce G.F. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344 (1990) 467-468
103. Rodriguez-Carreno M.P., Nelson M.S., Botten J., Smith-Nixon K., Buchmeier M.J., and Whitton J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335 (2005) 87-98
104. Rojek J.M., Lee A.M., Nguyen N., Spiropoulou C.F., and Kunz S. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J. Virol. 82 (2008) 6045-6051
105. Ruiz-Jarabo C.M., Ly C., Domingo E., and de la Torre J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308 (2003) 37-47
106. Sakai J., Nohturfft A., Goldstein J.L., and Brown M.S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J. Biol. Chem. 273 (1998) 5785-5793
107. Salvato M., Borrow P., Shimomaye E., and Oldstone M.B. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 65 (1991) 1863-1869
108. Salvato M.S. Molecular biology of the prototype arenavirus, lymphocytic choriomeningitis virus. In: Salvato M.S. (Ed). The Arenaviridae vol. 1 (1993), Plenum, New York 133-156
109. Salvato M.S., Schweighofer K.J., Burns J., and Shimomaye E.M. Biochemical and immunological evidence that the 11 kDa zinc-binding protein of lymphocytic choriomeningitis virus is a structural component of the virus. Virus Res. 22 (1992) 185-198
110. Sanchez A.B., and de la Torre J.C. Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 79 (2005) 7262-7268
111. Sanchez A.B., and de la Torre J.C. Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology 350 (2006) 370-380
112. Sanchez A.B., Perez M., Cornu T., and de la Torre J.C. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 79 (2005) 11071-11081
113. Sanchez A.J., Vincent M.J., and Nichol S.T. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J. Virol. 76 (2002) 7263-7275
114. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005) 739-789
115. Sears P., and Wong C.H. Carbohydrate mimetics: a new strategy for tackling the problem of carbohydrate-mediated biological recognition. Angew. Chem. Int. Ed. Engl. 38 (1999) 2300-2324 (pii)
116. Sears P., and Wong C.H. Toward automated synthesis of oligosaccharides and glycoproteins. Science 291 (2001) 2344-2350
117. Seidah N.G., Mowla S.J., Hamelin J., Mamarbachi A.M., Benjannet S., Toure B.B., Basak A., Munzer J.S., Marcinkiewicz J., Zhong M., Barale J.C., Lazure C., Murphy R.A., Chretien M., and Marcinkiewicz M. Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 1321-1326
118. Smallwood S., Cevik B., and Moyer S.A. Intragenic complementation and oligomerization of the L subunit of the sendai virus RNA polymerase. Virology 304 (2002) 235-245
119. Smallwood S., and Moyer S.A. The L polymerase protein of parainfluenza virus 3 forms an oligomer and can interact with the heterologous Sendai virus L, P and C proteins. Virology 318 (2004) 439-450
120. Strecker T., Eichler R., Meulen J., Weissenhorn W., Dieter Klenk H., Garten W., and Lenz O. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J. Virol. 77 (2003) 10700-10705
121. Su H.L., Liao C.L., and Lin Y.L. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. J. Virol. 76 (2002) 4162-4171
122. Sucheck S.J., Greenberg W.A., Tolbert T.J., and Wong C.H. Design of small molecules that recognize RNA: development of aminoglycosides as potential antitumor agents that target oncogenic RNA sequences this work was supported by the NIH. We thank Professor Peter Voght for his suggestion of the oncogenic RNA sequences as targets. Angew. Chem. Int. Ed. Engl. 39 (2000) 1080-1084 (pii)
123. Sucheck S.J., and Shue Y.K. Combinatorial synthesis of aminoglycoside libraries. Curr. Opin. Drug Discov. Dev. 4 (2001) 462-470
124. Sucheck S.J., and Wong C.H. RNA as a target for small molecules. Curr. Opin. Chem. Biol. 4 (2000) 678-686
125. Sun M., Rothermel T.A., Shuman L., Aligo J.A., Xu S., Lin Y., Lamb R.A., and He B. Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J. Virol. 78 (2004) 5068-5078
126. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., and Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11 (2005) 435-443
127. Tordo N., De Haan P., Goldbach R., and Poch O. Evolution of negative-stranded RNA genomes. Semin. Virol. 3 (1992) 341-357
128. Tortorici M.A., Albarino C.G., Posik D.M., Ghiringhelli P.D., Lozano M.E., Rivera Pomar R., and Romanowski V. Arenavirus nucleocapsid protein displays a transcriptional antitermination activity in vivo. Virus Res. 73 (2001) 41-55
129. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
130. Urata S., Noda T., Kawaoka Y., Yokosawa H., and Yasuda J. Cellular factors required for Lassa virus budding. J. Virol. 80 (2006) 4191-4195
131. Versteeg G.A., van de Nes P.S., Bredenbeek P.J., and Spaan W.J. The coronavirus spike protein induces ER stress and upregulation of intracellular chemokine mRNA concentrations. J. Virol. 1 (2007) 1
132. Vincent M.J., Sanchez A.J., Erickson B.R., Basak A., Chretien M., Seidah N.G., and Nichol S.T. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. 77 (2003) 8640-8649
133. Wachsman M.B., Lopez E.M., Ramirez J.A., Galagovsky L.R., and Coto C.E. Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antivir. Chem. Chemother. 11 (2000) 71-77
134. Wang S., Huber P.W., Cui M., Czarnik A.W., and Mei H.Y. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry 37 (1998) 5549-5557
135. Wells J.A., and de Vos A.M. Hematopoietic receptor complexes. Annu. Rev. Biochem. 65 (1996) 609-634
136. Wilson W.D., and Li K. Targeting RNA with small molecules. Curr. Med. Chem. 7 (2000) 73-98
137. Yarnell W.S., and Roberts J.W. Mechanism of intrinsic transcription termination and antitermination. Science 284 (1999) 611-615
138. Ye J., Rawson R.B., Komuro R., Chen X., Dave U.P., Prywes R., Brown M.S., and Goldstein J.L. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell. 6 (2000) 1355-1364
139. Ye X.-S., and Zhang L.H. Aminoglycoside mimetics as small-molecule drugs targeting RNA. Curr. Med. Chem. 9 (2002) 929-939
140. York J., Romanowski V., Lu M., and Nunberg J.H. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J. Virol. 78 (2004) 10783-10792
141. Zapp M.L., Stern S., and Green M.R. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74 (1993) 969-978
142. Zhang K., and Kaufman R.J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66 (2006) S102-109
143. Zhang K., Shen X., Wu J., Sakaki K., Saunders T., Rutkowski D.T., Back S.H., and Kaufman R.J. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 124 (2006) 587-599
144. Zinkernagel R.M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263 (2002) 1-5